Akero Therapeutics
BiotechUnited States
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
5
Indications↗
Distinct diseases across all programs
8
Clinical Trials↗
All sponsored trials (all statuses)
11
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 31
Phase 21
By Therapeutic Area
top 3
Gastroenterology
133%
Metabolic & Endocrine
133%
Infectious Disease
133%
R&D Momentum
30/100
Pipeline Velocity
0/100
Trial Completion Rate
100/100
Pipeline Concentration
33/100
Pipeline Freshness
71/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Key Events
Jun 26, 2026TrialA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Mar 17, 2026TrialHARMONY: Efruxifermin in NASH
Sep 4, 2024TrialA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Nov 10, 2023TrialA Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Jul 30, 2021TrialA Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
Apr 23, 2021FDAZynlonta — ZYNLONTA
Feb 16, 2021TrialA Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Jan 10, 2020FDAValium — VALTOCO
Details
Company Info
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease
Regulatory
Regulatory Timeline
19826 events
FDAJan 1
Busulfex — MYLERAN
Application NDA009386 (NDA)
FDAJan 1
Tabloid — THIOGUANINE
Application NDA012429 (NDA)
FDAJan 1
Valium — VALIUM
Application NDA016087 (NDA)
FDAJan 1
Valium — VALIUM
Application NDA013263 (NDA)
FDAJan 1
Valium — VALRELEASE
Application NDA018179 (NDA)
FDAJan 1
Leukeran — LEUKERAN
Application NDA010669 (NDA)
19901 event
FDADec 5
Valium — DIAZEPAM
Application NDA020124 (NDA)
19931 event
FDAJun 18
Valium — DIZAC
Application NDA019287 (NDA)
19972 events
FDAJul 29
Valium — DIASTAT
Application NDA020648 (NDA)
FDAMay 29
Coreg — COREG
Application NDA020297 (NDA)
19991 event
FDAFeb 4
Busulfex — BUSULFEX
Application NDA020954 (NDA)
20011 event
FDANov 20
Avodart — AVODART
Application NDA021319 (NDA)
20021 event
FDAMay 29
Aciphex — ACIPHEX
Application NDA020973 (NDA)
20042 events
FDADec 15
Lunesta — LUNESTA
Application NDA021476 (NDA)
FDANov 10
Lovaza — LOVAZA
Application NDA021654 (NDA)
20061 event
FDAOct 20
Coreg — COREG CR
Application NDA022012 (NDA)
20131 event
FDAMar 26
Aciphex — ACIPHEX SPRINKLE
Application NDA204736 (NDA)
20141 event
FDAMay 8
Zontivity — ZONTIVITY
Application NDA204886 (NDA)
20201 event
FDAJan 10
Valium — VALTOCO
Application NDA211635 (NDA)
20211 event
FDAApr 23
Zynlonta — ZYNLONTA
Application BLA761196 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)